OBJECTIVES: To describe a step-by-step guide for using the first transperineal targeted prostate biopsy platform available in the USA. PATIENTS AND METHODS: A total of 32 men with elevated prostate-specific antigen (PSA) levels were diagnosed with a region of interest on multiparametric magnetic resonance imaging (mpMRI) between February 2017 and January 2018. The transperineal targeted prostate biopsy procedure was accomplished via a transperineal approach and used a stepper, combined with advanced mpMRI/transrectal ultrasound fusion software, to perform targeted prostate biopsy. The detection of overall and clinically significant prostate cancer (PCa) was assessed as well as the rate of complications. RESULTS: The median patient age was 68.0 years and the median PSA was 8.0 ng/mL. Two patients (6%) were active surveillance candidates and 16 (50%) had a prior negative prostate biopsy. The detection rates for overall and clinically significant PCa were 81% and 59%, respectively. The two candidates for active surveillance and eight of the patients with a prior negative prostate biopsy had clinically significant PCa confirmed on targeted biopsy. There were no peri-operative complications. CONCLUSION: These results demonstrate the promising potential of the first transperineal targeted prostate biopsy platform in the USA as an alternative diagnostic method for PCa.
OBJECTIVES: To describe a step-by-step guide for using the first transperineal targeted prostate biopsy platform available in the USA. PATIENTS AND METHODS: A total of 32 men with elevated prostate-specific antigen (PSA) levels were diagnosed with a region of interest on multiparametric magnetic resonance imaging (mpMRI) between February 2017 and January 2018. The transperineal targeted prostate biopsy procedure was accomplished via a transperineal approach and used a stepper, combined with advanced mpMRI/transrectal ultrasound fusion software, to perform targeted prostate biopsy. The detection of overall and clinically significant prostate cancer (PCa) was assessed as well as the rate of complications. RESULTS: The median patient age was 68.0 years and the median PSA was 8.0 ng/mL. Two patients (6%) were active surveillance candidates and 16 (50%) had a prior negative prostate biopsy. The detection rates for overall and clinically significant PCa were 81% and 59%, respectively. The two candidates for active surveillance and eight of the patients with a prior negative prostate biopsy had clinically significant PCa confirmed on targeted biopsy. There were no peri-operative complications. CONCLUSION: These results demonstrate the promising potential of the first transperineal targeted prostate biopsy platform in the USA as an alternative diagnostic method for PCa.
Authors: Axel Heidenreich; Patrick J Bastian; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Theodor van der Kwast; Malcolm Mason; Vsevolod Matveev; Thomas Wiegel; F Zattoni; Nicolas Mottet Journal: Eur Urol Date: 2013-10-06 Impact factor: 20.096
Authors: Caroline M Moore; Veeru Kasivisvanathan; Scott Eggener; Mark Emberton; Jurgen J Fütterer; Inderbir S Gill; Robert L Grubb Iii; Boris Hadaschik; Laurence Klotz; Daniel J A Margolis; Leonard S Marks; Jonathan Melamed; Aytekin Oto; Suzanne L Palmer; Peter Pinto; Philippe Puech; Shonit Punwani; Andrew B Rosenkrantz; Ivo G Schoots; Richard Simon; Samir S Taneja; Baris Turkbey; Osamu Ukimura; Jan van der Meulen; Arnauld Villers; Yuji Watanabe Journal: Eur Urol Date: 2013-03-20 Impact factor: 20.096
Authors: M Minhaj Siddiqui; Soroush Rais-Bahrami; Baris Turkbey; Arvin K George; Jason Rothwax; Nabeel Shakir; Chinonyerem Okoro; Dima Raskolnikov; Howard L Parnes; W Marston Linehan; Maria J Merino; Richard M Simon; Peter L Choyke; Bradford J Wood; Peter A Pinto Journal: JAMA Date: 2015-01-27 Impact factor: 56.272
Authors: H A Vargas; A M Hötker; D A Goldman; C S Moskowitz; T Gondo; K Matsumoto; B Ehdaie; S Woo; S W Fine; V E Reuter; E Sala; H Hricak Journal: Eur Radiol Date: 2015-09-22 Impact factor: 5.315
Authors: James L Mohler; Andrew J Armstrong; Robert R Bahnson; Anthony Victor D'Amico; Brian J Davis; James A Eastham; Charles A Enke; Thomas A Farrington; Celestia S Higano; Eric M Horwitz; Michael Hurwitz; Christopher J Kane; Mark H Kawachi; Michael Kuettel; Richard J Lee; Joshua J Meeks; David F Penson; Elizabeth R Plimack; Julio M Pow-Sang; David Raben; Sylvia Richey; Mack Roach; Stan Rosenfeld; Edward Schaeffer; Ted A Skolarus; Eric J Small; Guru Sonpavde; Sandy Srinivas; Seth A Strope; Jonathan Tward; Dorothy A Shead; Deborah A Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2016-01 Impact factor: 11.908
Authors: Michael Tzeng; Eliza Cricco-Lizza; Bashir Al Hussein Al Awamlh; Morgan Pantuck; Daniel J Margolis; Miko Yu; Jim Hu Journal: BMJ Surg Interv Health Technol Date: 2019-11-20